Evidence map›Paper›PMID 32679765›Full record

ArticleInternational journal of molecular sciences2020

LY75 Suppression in Mesenchymal Epithelial Ovarian Cancer Cells Generates a Stable Hybrid EOC Cellular Phenotype, Associated with Enhanced Tumor Initiation, Spreading and Resistance to Treatment in Orthotopic Xenograft Mouse Model.

Sadia Mehdi, Elizabeth Macdonald, Kristianne Galpin, David A Landry, Galaxia Rodriguez, Barbara Vanderhyden, Dimcho Bachvarov

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sadia MehdiDepartment of Molecular Medicine, Université Laval, Québec City, QC G1V 0A6, Canada.
Elizabeth MacdonaldDepartment of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada.ORCID 0000-0002-3154-9632
Kristianne GalpinDepartment of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada.ORCID 0000-0002-4199-6874
David A LandryDepartment of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Galaxia RodriguezDepartment of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Barbara VanderhydenDepartment of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada.ORCID 0000-0002-7644-7189
Dimcho BachvarovDepartment of Molecular Medicine, Université Laval, Québec City, QC G1V 0A6, Canada.
University of Ottawa · CAHôtel-Dieu de Québec · CA

Funding

Cancer Research Society of Canada 21110
6 · The paper itself

Abstract

The implications of the epithelial-mesenchymal transition (EMT) mechanisms in the initiation and progression of epithelial ovarian cancer (EOC) remain poorly understood. We have previously shown that suppression of the antigen receptor LY75 directs mesenchymal-epithelial transition (MET) in EOC cell lines with the mesenchymal phenotype, associated with the loss of Wnt/β-catenin signaling activity. In the present study, we used the LY75-mediated modulation of EMT in EOC cells as a model in order to investigate

Indexed as

Gene Expression Regulation, NeoplasticAnimalsAntigens, CDAntineoplastic AgentsCarboplatinCarcinogenesisCarcinoma, Ovarian EpithelialCell Line, TumorDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionFemaleHumansLectins, C-TypeMiceMice, SCIDMinor Histocompatibility AntigensAntigens, CDAntineoplastic AgentsCarboplatinDEC-205 receptorLectins, C-TypeMinor Histocompatibility AntigensReceptors, Cell Surfacecancer stem cells (CSCs)epithelial–mesenchymal transition (EMT)epithelial ovarian cancerhybrid cellular phenotypeLy75orthotopic xenograft mouse modelWnt/β catenin pathway

Identifiers

PMID32679765
PMCPMC7404269
OpenAlexW3042521574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.